HC Wainwright Issues Positive Forecast for Palvella Therapeutics (NASDAQ:PVLA) Stock Price

Palvella Therapeutics (NASDAQ:PVLA) had its target price hoisted by HC Wainwright from $95.00 to $190.00 in a report published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the stock. Lifesci Capital assumed coverage on shares of Palvella Therapeutics in a report on Monday, August 4th. They set an “outperform” rating and a $90.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Wednesday, October 8th. Canaccord Genuity Group lifted their price objective on Palvella Therapeutics from $66.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Stifel Nicolaus upped their price objective on Palvella Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Finally, Raymond James Financial set a $54.00 target price on Palvella Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $97.58.

Palvella Therapeutics Stock Performance

Shares of NASDAQ:PVLA traded down $0.80 during trading on Thursday, hitting $77.83. 104,830 shares of the stock were exchanged, compared to its average volume of 116,017. Palvella Therapeutics has a 1-year low of $11.17 and a 1-year high of $83.00. The company has a market capitalization of $860.80 million, a price-to-earnings ratio of -20.54 and a beta of -0.05. The company’s fifty day simple moving average is $66.13 and its 200-day simple moving average is $42.75.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Thursday, August 14th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). On average, research analysts forecast that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Palvella Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of PVLA. Clio Asset Management LLC bought a new position in Palvella Therapeutics during the 2nd quarter worth approximately $2,063,000. Woodline Partners LP acquired a new stake in Palvella Therapeutics in the first quarter worth $5,435,000. Goldman Sachs Group Inc. bought a new position in shares of Palvella Therapeutics during the first quarter worth $533,000. Frazier Life Sciences Management L.P. grew its holdings in shares of Palvella Therapeutics by 5.5% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company’s stock valued at $19,313,000 after buying an additional 36,120 shares during the period. Finally, Royce & Associates LP acquired a new position in shares of Palvella Therapeutics in the 1st quarter valued at $2,002,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.